•
Patient data from
8,820
men with
mCRPC enrolled onto 9 phase III trials.
•
Site of metastases:
lymph node only
,
bone with or without LN
, any
lung
metastases (but
no liver), and any
liver
metastases.
•
Specific sites of metastases in men with mCRPC are associated with differential OS:
LN>Bone>lung>liver
•
These data may help in
treatment decisions
,
design of clinical trials
, and understanding the
variation
in biology of different sites of metastases
in men with mCRPC.
